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OBJECTIVES: To compare outcomes of multiple sclerosis (MS)
patients treated with either glatiramer acetate (GA) or low dose
interferon beta 1-a (IFN-b-1a [IM]). METHODS: Data were
obtained from i3’s Lab Rx Database from July 2001 to June
2006. We established an “intent-to-treat” (ITT) cohort
(N = 1282) of patients diagnosed with MS who began therapy
on either GA or IFN-b-1a [IM] and had continuous insurance
coverage from 6 months before to 24 months after the identiﬁed
ﬁrst use of the medication. We also created a “continuous use”
(CU) cohort (n = 639) of individuals who, in addition to the
criteria listed above, used either GA or IFN-b-1a [IM] within 28
days of the end of the two year post-period. Using multivariate
regressions, we examined both the two-year total direct medical
costs and the likelihood of relapse associated with the use of
each MS medication. Relapse is deﬁned as either being hospi-
talized with a diagnosis of MS or being diagnosed with MS
during an outpatient visit and then prescribed steroids within a
7-day period. All regression analyses evaluated a wide range of
factors that may affect outcomes. RESULTS: In the ITT cohort,
compared to those who initiated therapy on IFN-b-1a [IM],
patients who started therapy on GA had a signiﬁcantly lower
two-year risk of relapse (10.01% v 5.18%; p = 0.0034) and
signiﬁcantly lower two-year total medical costs ($44,201 v
$41,121; p = 0.0294). In the CU cohort, compared to those
who used IFN-b-1a [IM], patients who used GA also had a
signiﬁcantly lower two-year risk of relapse (7.25% v 2.16%;
P = 0.0048) and signiﬁcantly lower total medical costs ($67,744
v $63,714; P = 0.0445). CONCLUSIONS: Results from this
study indicate that, compared to the use of IFN beta-1a [IM],
GA use is associated with signiﬁcantly lower probability of
relapse and signiﬁcantly lower two-year total direct medical
costs.
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OBJECTIVES: To assess the cost-effectiveness of the Versatis
lidocaine 5% medicated plaster relative to gabapentin and 300
and 600 mg/day pregabalin in the treatment of post-herpetic
neuralgia (PHN) from the perspective of the society in The
Netherlands. METHODS: The costs and beneﬁts of the three
treatment strategies were assessed over a six-month time
horizon using a Markov model of PHN. The model structure
allowed for differences in costs, utilities and transition prob-
abilities between the initial 30-day run-in period and mainte-
nance therapy and also took account of add-in medication and
drugs received by patients discontinuing therapy. Transition
probabilities were based on clinical trials and Delphi panel esti-
mates. Quantities/types of resource use and add-in/switch medi-
cations were obtained from a Delphi panel; cost data were from
ofﬁcial price tariffs; utilities were derived from the literature.
Lidocaine-treated patients were assumed to receive 1.03
plasters/day based on US prescribing data. RESULTS: The
average patient receiving the lidocaine plaster accrued 0.401
quality-adjusted life-years (QALYs) over six months – 0.065
more than gabapentin, 0.056 more than 300 mg pregabalin and
0.052 more than 600 mg pregabalin. The cost of the lidocaine
plaster (€1180/patient) was also higher than that for gabapentin
(€1121/patient), for 300 mg pregabalin (€1115/patient), but
lower than for 600 mg pregabalin (€1386/patient). Subse-
quently, the lidocaine plaster cost €908/QALY relative to gaba-
pentin; €1161/QALY relative to 300 mg/day pregabalin and the
lidocaine plaster is dominant relative to 600 mg/day pregabalin.
Probabilistic sensitivity analysis demonstrated we can be more
than 99% conﬁdent that the lidocaine plaster is cost-effective
relative to gabapentin, 300 mg pregabalin, and 600 mg pre-
gabalin, when society is willing to pay at least €20,000 to gain
one QALY. The lidocaine plaster cost €44 per additional month
with sufﬁcient pain relief and no intolerable side effects relative
to gabapentin, €65 relative to 300 mg pregabalin and is domi-
nant relative to 600 mg pregabalin. CONCLUSIONS: The Ver-
satis lidocaine 5% medicated plaster is a highly cost-effective
alternative to gabapentin and pregabalin for the treatment of
PHN in The Netherlands.
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